Inventor · disambiguated record
Brian M. Fox
Also filed as: FOX BRIAN · FOX BRIAN M · FOX BRIAN MATTHEW
25 granted patents·30 pending applications·140 citations·filing 2003–2025
95Inventor score
Files withDENALI THERAPEUTICS INC29AMGEN INC19JAPAN TOBACCO INC3NICO THERAPEUTICS INC3TENVIE THERAPEUTICS INC1
Top patents by PatentIndex Score
55 records- 0197US9896458B2Compounds, compositions and methodsDENALI THERAPEUTICS INC·Filed 2017·Granted Feb 20, 2018·23 cites·6 claims
- 0297US9815850B2Compounds, compositions and methodsDENALI THERAPEUTICS INC·Filed 2017·Granted Nov 14, 2017·36 cites·41 claims
- 0394US9623018B2Processes of making and crystalline forms of a MDM2 inhibitorAMGEN INC·Filed 2016·Granted Apr 18, 2017·6 cites·28 claims
- 0491US11306077B2Compounds, compositions and methodsDENALI THERAPEUTICS INC·Filed 2021·Granted Apr 19, 2022·2 cites·47 claims
- 0588US9593129B2Piperidinone derivatives as MDM2 inhibitors for the treatment of cancerAMGEN INC·Filed 2016·Granted Mar 14, 2017·5 cites·18 claims
- 0688US9296736B2Piperidinone derivatives as MDM2 inhibitors for the treatment of cancerAMGEN INC·Filed 2014·Granted Mar 29, 2016·7 cites·13 claims
- 0787US2024300892A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2023·Application pending·0 cites
- 0886US10604535B2Compounds, compositions and methodsDENALI THERAPEUTICS INC·Filed 2018·Granted Mar 31, 2020·3 cites·18 claims
- 0986US10131676B2Compounds, compositions and methodsDENALI THERAPEUTICS INC·Filed 2017·Granted Nov 20, 2018·3 cites·33 claims
- 1086US9376425B2Heterocyclic compounds as MDM2 inhibitors for the treatment of cancerAMGEN INC·Filed 2012·Granted Jun 28, 2016·12 cites·37 claims
- 1185US12358928B2Compounds, compositions and methodsDENALI THERAPEUTICS INC·Filed 2023·Granted Jul 15, 2025·0 cites·8 claims
- 1285US9801867B2Processes of making and crystalline forms of a MDM2 inhibitorAMGEN INC·Filed 2016·Granted Oct 31, 2017·2 cites·30 claims
- 1384US2025388601A1Compounds, Compositions and MethodsDENALI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1484US2023301974A1Processes of making and crystalline forms of a mdm2 inhibitorAMGEN INC·Filed 2023·Application pending·0 cites
- 1583US11203600B2Kinase inhibitors and uses thereofDENALI THERAPEUTICS INC·Filed 2019·Granted Dec 21, 2021·2 cites·24 claims
- 1683US7244727B2Fused bicyclic nitrogen-containing heterocyclesJAPAN TOBACCO INC·Filed 2003·Granted Jul 17, 2007·22 cites·57 claims
- 1780US11236100B2Modulators of eukaryotic initiation factor 2B, compositions and methodsDENALI THERAPEUTICS INC·Filed 2018·Granted Feb 1, 2022·1 cites·30 claims
- 1880US2022169611A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2022·Application pending·0 cites
- 1980US2025011338A1Kinase Inhibitors and Uses ThereofDENALI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2079US2024140919A1Modulators of eukaryotic initiation factor 2DENALI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2178US7300932B2Pyrrolo[1,2-b]pyridazine derivativesJAPAN TOBACCO INC·Filed 2004·Granted Nov 27, 2007·14 cites·17 claims
- 2276US2023250072A1Modulators of eukaryotic initiation factor 2DENALI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2375US11851440B2Modulators of eukaryotic initiation factor 2B, compositions and methodsDENALI THERAPEUTICS INC·Filed 2021·Granted Dec 26, 2023·0 cites·18 claims
- 2475US2022280496A1Processes of making and crystalline forms of a mdm2 inhibitorAMGEN INC·Filed 2021·Application pending·0 cites
- 2574US2021179560A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2020·Application pending·0 cites
- 2674US2020281912A1Processes of making and crystalline forms of a mdm2 inhibitorAMGEN INC·Filed 2019·Application pending·0 cites
- 2773US2023043400A1Compounds, Compositions and MethodsDENALI THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2872US9365522B2Pyrazole amide derivativeAMGEN INC·Filed 2015·Granted Jun 14, 2016·2 cites·14 claims
- 2972US2024025915A1Solid forms of 4-(3,3-difluoro-2,2-dimethyl-propanoyl)-3,5-dihydro-2h-pyrido[3,4-f][1,4]oxazepine-9-carbonitrileDENALI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3070US2018092898A1Processes of making and crystalline forms of a mdm2 inhibitorAMGEN INC·Filed 2017·Application pending·0 cites
- 3169US12180211B2Compounds, compositions and methodsDENALI THERAPEUTICS INC·Filed 2021·Granted Dec 31, 2024·0 cites·5 claims
- 3269US12129263B2Kinase inhibitors and uses thereofDENALI THERAPEUTICS INC·Filed 2021·Granted Oct 29, 2024·0 cites·19 claims
- 3369US2020317691A1Compounds, Compositions and MethodsDENALI THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3468US11958840B2Compounds, compositions and methodsDENALI THERAPEUTICS INC·Filed 2022·Granted Apr 16, 2024·0 cites·45 claims
- 3568US2025295647A1Processes of making and crystalline forms of a mdm2 inhibitorAMGEN INC·Filed 2024·Application pending·0 cites
- 3667US11851433B2Compounds, compositions and methodsDENALI THERAPEUTICS INC·Filed 2021·Granted Dec 26, 2023·0 cites·17 claims
- 3767US2019062276A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2018·Application pending·0 cites
- 3866US2024317776A1Solid forms of 4-(3,3-difluoro-2,2-dimethyl-propanoyl)-3,5-dihydro-2h-pyrido[3,4-f][1,4]oxazepine-9-carbonitrileDENALI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3965US11072618B2Compounds, compositions and methodsDENALI THERAPEUTICS INC·Filed 2019·Granted Jul 27, 2021·0 cites·17 claims
- 4065US2025388595A1Modulators of eukaryotic initiation factor 2b, compositions and methodsDENALI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4165US2014011796A1Piperidinone derivatives as mdm2 inhibitors for the treatment of cancerAMGEN INC·Filed 2013·Application pending·0 cites
- 4264US2021130308A1Modulators of eukaryotic initiation factor 2DENALI THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4364US2017144971A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2017·Application pending·0 cites
- 4461US2025361234A1Compounds, compositions, and methodsNICO THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4559US2025171462A1Compounds, compositions, and methodsNICO THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4659US2025145592A1Compounds, compositions, and methodsNICO THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4759US2025197399A1Compounds, compositions, and methodsTENVIE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4855US11174262B2Compounds, compositions and methodsDENALI THERAPEUTICS INC·Filed 2019·Granted Nov 16, 2021·0 cites·16 claims
- 4954US2023357162A1Compounds, compositions and methodsDENALI THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 5053US2023348437A1Compounds, compositions and methodsDENALI THERAPEUTICS INC·Filed 2021·Application pending·0 cites
Showing the top 50 of 55 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Brian M. Fox files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →